237 related articles for article (PubMed ID: 19152631)
1. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
Nisius B; Göller AH; Bajorath J
Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
3. A binary QSAR model for classification of hERG potassium channel blockers.
Thai KM; Ecker GF
Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
[TBL] [Abstract][Full Text] [Related]
4. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
[TBL] [Abstract][Full Text] [Related]
5. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
[TBL] [Abstract][Full Text] [Related]
6. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
Leong MK
Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship models for predicting biological properties, developed by combining structure- and ligand-based approaches: an application to the human ether-a-go-go-related gene potassium channel inhibition.
Coi A; Massarelli I; Saraceno M; Carli N; Testai L; Calderone V; Bianucci AM
Chem Biol Drug Des; 2009 Oct; 74(4):416-33. PubMed ID: 19751420
[TBL] [Abstract][Full Text] [Related]
8. Classification models for HERG inhibitors by counter-propagation neural networks.
Thai KM; Ecker GF
Chem Biol Drug Des; 2008 Oct; 72(4):279-89. PubMed ID: 18844674
[TBL] [Abstract][Full Text] [Related]
9. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
10. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
Kireeva N; Kuznetsov SL; Bykov AA; Tsivadze AY
SAR QSAR Environ Res; 2013; 24(2):103-17. PubMed ID: 23152964
[TBL] [Abstract][Full Text] [Related]
11. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
12. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
13. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
14. Bias-correction of regression models: a case study on hERG inhibition.
Hansen K; Rathke F; Schroeter T; Rast G; Fox T; Kriegl JM; Mika S
J Chem Inf Model; 2009 Jun; 49(6):1486-96. PubMed ID: 19435326
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
16. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Hancox JC; James AF
Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
[TBL] [Abstract][Full Text] [Related]
17. Prediction of hERG potassium channel affinity by the CODESSA approach.
Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
[TBL] [Abstract][Full Text] [Related]
18. Tuning out of hERG.
Aronov AM
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
[TBL] [Abstract][Full Text] [Related]
19. Determination of hERG channel blockers using a decision tree.
Gepp MM; Hutter MC
Bioorg Med Chem; 2006 Aug; 14(15):5325-32. PubMed ID: 16616507
[TBL] [Abstract][Full Text] [Related]
20. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
